Mirum Pharmaceuticals, Inc. Common Stock Earnings Dividend

Mirum Pharmaceuticals, Inc. Common Stock’s revenue jumped 37.92% since last year same period to $176.24Mn in the Q2 2026. On a quarterly growth basis, Mirum Pharmaceuticals, Inc. Common Stock has generated 10.23% jump in its revenue since last 3-months.

Mirum Pharmaceuticals, Inc. Common Stock’s net profit fell -1047.02% since last year same period to $-67.23Mn in the Q2 2026. On a quarterly growth basis, Mirum Pharmaceuticals, Inc. Common Stock has generated 91.49% jump in its net profits since last 3-months.

Mirum Pharmaceuticals, Inc. Common Stock’s net profit margin fell -731.65% since last year same period to -38.14% in the Q2 2026. On a quarterly growth basis, Mirum Pharmaceuticals, Inc. Common Stock has generated 92.28% jump in its net profit margins since last 3-months.

Mirum Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.61 - a 20.78% jump from last quarter’s estimates.

Mirum Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.61.

Mirum Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -566.67% since last year same period to -0.8 in the Q2 2026. This indicates that the Mirum Pharmaceuticals, Inc. Common Stock has generated -566.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.